Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients

  • Authors:
    • Shigenori Homma
    • Mamoru Harada
    • Hirohisa Yano
    • Sachiko Ogasawara
    • Shigeki Shichijo
    • Satoko Matsueda
    • Nobukazu Komatsu
    • Hiroki Shomura
    • Yoshiaki Maeda
    • Yuji Sato
    • Satoru Todo
    • Kyogo Itoh
  • View Affiliations

  • Published online on: September 1, 2006     https://doi.org/10.3892/ijo.29.3.577
  • Pages: 577-587
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Squamous cell carcinoma antigen (SCCA) is a useful marker for SCCs. In this study, we attempted to identify SCCA-derived peptides that could be applied in the development of specific immunotherapy for HLA-A24+ cancer patients with SCC or non-SCC. A variety of SCC and non-SCC lines were examined for their expression of SCCA mRNA using quantitative PCR. SCCA protein expression in cancer tissues was investigated by immunohistochemical staining. Thereafter, SCCA-derived peptide candidates were prepared based on their binding motifs to HLA-A24 molecules. Among these peptides, SCCA-derived peptides that were frequently recognized by humoral immunity were further tested for their ability to induce cancer-reactive cytotoxic T lymphocytes (CTLs) from the peripheral blood mononuclear cells of HLA-A24+ patients with SCC or non-SCC. As a result, the majority of SCC lines and tissues were positive for SCCA both at mRNA and protein levels. By contrast, non-SCC cancer tissues hardly expressed it at the protein level, although adenocarcinoma cell lines partly expressed it at the mRNA level. Four SCCA-derived peptides were frequently recognized by immunoglobulin G of both SCC and non-SCC cancer patients. Among these peptides, both the SCCA112-120 and SCCA215-224 peptides were found to effectively induce peptide-specific CTLs toward HLA-A24+ SCCA+ cancer cells from the peripheral blood mononuclear cells of both SCC and non-SCC cancer patients. Two newly identified SCCA-derived peptides with the ability to induce CTL activity in both SCC and non-SCC cancer patients may be applicable to specific immunotherapy for HLA-A24+ cancer patients with SCC, but not those with non-SCC.

Related Articles

Journal Cover

September 2006
Volume 29 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Homma, S., Harada, M., Yano, H., Ogasawara, S., Shichijo, S., Matsueda, S. ... Itoh, K. (2006). Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients. International Journal of Oncology, 29, 577-587. https://doi.org/10.3892/ijo.29.3.577
MLA
Homma, S., Harada, M., Yano, H., Ogasawara, S., Shichijo, S., Matsueda, S., Komatsu, N., Shomura, H., Maeda, Y., Sato, Y., Todo, S., Itoh, K."Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients". International Journal of Oncology 29.3 (2006): 577-587.
Chicago
Homma, S., Harada, M., Yano, H., Ogasawara, S., Shichijo, S., Matsueda, S., Komatsu, N., Shomura, H., Maeda, Y., Sato, Y., Todo, S., Itoh, K."Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients". International Journal of Oncology 29, no. 3 (2006): 577-587. https://doi.org/10.3892/ijo.29.3.577